Navigation Links
ThromboGenics - Positive Microplasmin Phase II Data Published in Ophthalmology
Date:2/9/2010

ential breakthrough for the treatment of certain patients suffering from vitreoretinal pathologic conditions related to vitreomacular adhesion. Vitreomacular adhesion is thought to play a key role in numerous back of the eye conditions such as macular hole formation, and some forms of macular edema. Vitreomacular adhesion is also associated with much poorer prognosis in certain major eye conditions, including diabetic retinopathy and Age-Related Macular Degeneration (AMD).

ThromboGenics is now conducting an extensive Phase III program with microplasmin, referred to as MIVI-TRUST (Microplasmin IntraVitreous Injection - Traction Release without Surgical Treatment), for the non-surgical resolution of focal vitreomacular adhesion. The patient enrollment for the two Phase III trials was completed in 2009 ahead of schedule. The first results from this Phase III program are due in Q2 2010.

For a full discussion of the results from the Phase II trial (MIVI III), please refer to the Ophthalmology article.[1] Further information is also included in the ThromboGenics press release dated 30 June, 2008 (see http://www.thrombogenics.com).

Steve Pakola, MD, Chief Medical Officer of ThromboGenics and co-author of the Ophthalmology paper, commented, "We are very pleased to have had these results with microplasmin published in such a prestigious journal. The Phase II trial data discussed in the paper demonstrate the exciting potential of microplasmin in treating a range of important back of the eye diseases. We very much look forward to announcing the first results from our Phase III program with microplasmin by mid 2010."

About ThromboGe
'/>"/>

SOURCE ThromboGenics NV
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ThromboGenics NV - Q3 2009 Business Update
2. ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
3. ThromboGenics is Shortlisted for "Biotech Company of the Year" and "Licensing Deal of the Year" at Scrip Awards 2009
4. ThromboGenics NV Announces Business Update and Half Year Results 2009
5. ThromboGenics NV: Business Update
6. ThromboGenics Announces Business Update and 2008 Full Year Results
7. ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
8. ThromboGenics N.V.: Business Update
9. ThromboGenics Announces Half Year Results 2008
10. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
11. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/27/2014)... and TORONTO , Oct. ... www.generex.com ) (OTCQB: GNBT) today announced two presentations ... triggered by its novel proprietary cancer immunotherapeutic AE37 ... breast cancer patients. The AE37 cancer vaccine is ... Express, Inc. ( www.antigenexpress.com ). The presentations are ...
(Date:10/27/2014)... 2014 The “Molecular Diagnostic Market ... Technology (PCR, INAAT, DNA Sequencing), End User (Hospital, ... - Global Forecast to 2018” provides a detailed ... current market trends, and strategies impacting the global ... forecasts of the revenue and share analysis. , ...
(Date:10/27/2014)... 2014 Called the NOAH Protocol, ... several types of pediatric brain cancer. The implications ... over 30 years of research and development. Amber ... that one mom's determination can make a difference. ... trick-or-treating, and it’s only fitting that we’ve received ...
(Date:10/27/2014)... , Oct. 27, 2014 Pressure ... a worldwide leader in the development and sale ... life sciences research market, today announced that Professor ... a novel, accurate, highly reproducible, and robust method ... routine high-throughput protein analysis on small needle biopsy ...
Breaking Biology Technology:Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 3Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 4Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 2Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 3Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 4Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 5FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 2FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 3Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 2Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 3Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 4Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 5
... RAMAT GAN, Israel, June 8 EarlySense announced ... cleared for,marketing by the U.S. Food and Drug Administration ... Dutch notified body, in accordance with the,EC-Directive 93/42/EEC. Both ... home, hospital or clinical setting. In November 2007, EarlySense,announced ...
... Sirius Genomics, a developer of pharmacogenomic diagnostics, announced that ... its recent Annual General Meeting. The six-member Board consists ... Jim Heppell, Mr. Amos Michelson, Dr. Bradley Popovich and ... molecular diagnostics, commercialization and personalized medicine experience that is ...
... ... Pilest was recently selected by Solta Medical (parent company of Fraxel and Thermage) as ... more profound improvements when patients have undergone both procedures within a close time span. ... the cosmetic laser industry. , ...
Cached Biology Technology:EarlySense's EverOn(TM) System Receives FDA Clearance and CE Mark Certification 2Sirius Genomics Announces 2009 Board of Directors 2Orange County Laser Surgeon Nissan Pilest Tapped as Keynote Speaker at Fraxel & Thermage User Forum Held at Beckman Laser Institute 2Orange County Laser Surgeon Nissan Pilest Tapped as Keynote Speaker at Fraxel & Thermage User Forum Held at Beckman Laser Institute 3
(Date:10/29/2014)... registration is open for the Society ... Meeting. SIR 2015 is the one place ... and related health care professionals can come ... science and technologies being presented, discussed and ... in minimally invasive, image-guided medicine, SIR 2015 ...
(Date:10/29/2014)... on September 19, 2014, leading geneticist and humanitarian Prof. ... Sciences and Medicine at the University of Washington in ... Aviv University, was awarded the 2014 Lasker-Koshland Special Achievement ... honorary degree from TAU, Prof. King was the 2012-2013 ... for the past 18 years she has been the ...
(Date:10/29/2014)... Hebei, China — BGI Tech and Hebei Agricultural University ... Jujube genome. Jujube is the most economically important member ... particularly difficult to sequence due the high level of ... time that a genome in the Rhamnaceae (Buckthorn) family ... in Nature Communications . , Jujube ...
Breaking Biology News(10 mins):SIR 2015: Interventional radiology shapes tomorrow's medicine 2Geneticist and humanitarian: Prof. Mary-Claire King receives Lasker Award 2BGI Tech and Hebei Agricultural University complete the genome sequencing of the jujube tree 2
... examine the extent to which quercetin and trans-resveratrol ... cultures of human adipocytes treated with tumor necrosis ... and adipose tissue of obese, diabetic individuals. ... and trans-RSV followed by treatment with TNF-a. ...
... When prowling for a hook up, it,s not always the ... species of South American fish, brawn and stealth beat out ... series of published studies of a South American species of ... guppies, Syracuse University scientists have discovered how the interplay between ...
... environment, sea urchins literally eat through stone, using their teeth ... predators and protect themselves from the crashing surf on the ... rock-boring behavior is astonishing, scientists agree, but what is truly ... urchin teeth never, ever get dull. The secret of their ...
Cached Biology News:Study on effects of resveratrol and quercetin on inflammation and insulin resistance 2SU scientists find that in the evolutionary mating game, brawn and stealth rule 2SU scientists find that in the evolutionary mating game, brawn and stealth rule 3Ever-sharp urchin teeth may yield tools that never need honing 2
... has a long and outstanding history ... Several years ago we became aware ... was being modified to inject Xenopus ... redesigning the microdispenser to eliminate any ...
Coating : Poly-D-Lysine ,Surface : ECM/attachment factors ,Surface area : 9.6 cm2 ,Dim nominal : 35 mm x 10 mm ,Vol working : 2.5-3.0 ml ...
Rabbit polyclonal to Synapsin II ( Abpromise for all tested applications). entrezGeneID: 6854 SwissProtID: Q92777...
... primers are designed for sequencing inserts cloned ... T7, or T3 RNA polymerase promoters, or ... supplied at a concentration of 0.1 µg/µl ... in DNA sequencing reactions using SequiTherm™ EXCEL™ ...
Biology Products: